NMDA receptor pathways as drug targets

Nature Neuroscience

Volumn 5, Issue 11s, 2002, Pages 1039-1042

  Kemp, John A ^a   McKernan, Ruth M ^b  

^a Evotec Neurosciences GmbH   (Germany)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBTYPE;

ALZHEIMER DISEASE; CALCIUM TRANSPORT; DRUG TARGETING; ENHANCER REGION; ENZYME ACTIVE SITE; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; STROKE; SYNAPTIC TRANSMISSION;

ANIMALS; BRAIN; BRAIN DISEASES; DRUG DESIGN; DRUG INDUSTRY; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NEURAL PATHWAYS; NEUROSCIENCES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0036830627     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn936     Document Type: Review

References (37)

1. Watkins, J. C. in The NMDA Receptor (eds. Collingridge, G. L. & Watkins, J. C.) 1-30 (Oxford Univ. Press, New York, 1994).
2. McBain, C. J. & Mayer, M. L. N-methyl-D-aspartic acid receptor structure and function. Physiol. Rev. 74, 723-760 (1994).
3. Das, S. et al. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 393, 377-381 (1998).
4. Chatterton, J. E. et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 415, 793-798 (2002).
5. Kemp, J. A. & Kew, J. N. C. in Drugs And The Pharmaceutical Sciences Vol. 89 (ed. Leff, P.) 297-321 (Marcel Dekker, New York, 1998).
6. Williams, K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44, 851-859 (1993).
7. Kemp, J. A., Kew, J. N. C. & Gill, R. Handbook of Experimental Pharmacology Vol. 141 (eds. Jonas, P. & Monyer, H.) 495-527 (Springer, Berlin, 1999).
8. Lees, K. R. et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 355, 1949-1954 (2000).
9. Sacco, R. L. et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285, 1719-1728 (2001)
10. Gotti, B. et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J. Pharmacol. Exp. Ther. 247, 1211-1221 (1988).
11. Kew, J. N. C., Trube, G. & Kemp, J. A. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J. Physiol. (Lond.) 497, 761-772 (1996).
12. Gill, R. et al. Pharmacological characterization of Ro63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-01), a novel sinotype-selective N-methyl-D-aspartate antagonist. J. Pharmacol. Exp. Ther. 302, 940-948 (2002)
13. Schwarcz, R. J. Glutamate 2000: old dog, new tricks. Pharmacol. Exp. Ther. 296, 659-662 (2001).
14. Parsons, C. G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. 429, 71-78 (2001).
15. Boyce, S. et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 38, 611-623 (1999).
16. Chizh, B.A., Headley, P.M. & Tzschentke, T.M. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol. Sci. 22, 636-642 (2001).
17. Tranquillini, M. E. & Reggiani, A. Glycine-site antagonists and stroke. Expert Opin. Investig. Drugs 8, 1837-1848 (1999).
18. Leeson, P. D. & Iversen, L. L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem. 37, 4053-4067 (1994).
19. Chase, T. N., Oh, J. D. & Konitsiotis, S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247 (Suppl. 2), 36-42 (2000).
20. Del Dotto, P. et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov. Disord. 16, 515-520 (2001)
21. Lederer R., Radeke E. & Mondadori, C. Facilitation of social learning by treatment with an NMDA receptor antagonist. Behav. Neural Biol. 60, 220-224 (1993).
22. Mondadori, C., Weiskrantz, L., Buerki, H., Petschke, F. & Fagg, G. E. NMDA receptor antagonists can enhance or impair learning performance in animals. Exp. Brain Res. 75, 449-456 (1989).
23. Davis, M. The rde of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. Eur. J. Neurosci 16, 395-398 (2002).
24. Krystal, J. H. et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 7, 125-143 (1999).
25. Tsai, G. & Coyle, J. T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42, 165-179 (2002).
26. Tamminga, C. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12, 21-36 (1998).
27. Heresco-Levy, U. et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine or risperidone in schizophrenia. Am J.Psychiatry 159, 480-482 (2002).
28. Tsai, G., Yang, P., Chung L. C., Lange, N. & Coyle, J. T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 1081-1089 (1998).
29. Mothet, J. P. et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA 97, 4926-4931 (2000).
30. Wolosker, H., Blackshaw, S. & Snyder, S. H. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc. Natl. Acad. Sci. USA 96, 13409-13414 (1999).
31. Tang, Y. P. et al. Genetic enhancement of learning and memory in mice. Nature 401, 63-69 (1999).
32. Malayev, A., Gibbs, T. T. & Farb, D. H. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br. J. Pharmacol. 135, 901-909 (2002).
33. Husi, H., Ward, M. A., Choudhary, J. S., Blackstock, W. P. & Grant, S. G. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 3, 661-669 (2000).
34. Sheng, M. The postsynaptic NMDA-receptor-PSD-95 signaling complex in excitatory synapses of the brain. J. Cell. Sci. 114, 1251 (2001).
35. Hardingham, G. E., Fukunaga, Y. & Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405-414 (2002).
36. Lu, W. et al. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 29, 243-254 (2001).
37. Perin-Dureau, F., Rachline, J., Neyton, J. & Paoletti, P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J. Neurosci. 15, 5955-5965 (2002).